Background/Objectives: Children with autism spectrum disorder (ASD) frequently experience poor compliance with oral medication due to bitterness, unpleasant taste, and unsuitable dosage forms such as large tablets or capsules. Risperidone, a widely prescribed antipsychotic for managing ASD symptoms, is particularly challenging in this regard. The present study aimed to develop a novel sucrose-based microfiber drug delivery system to improve the palatability, acceptance, and bioavailability of risperidone in pediatric patients with ASD. Methods: Risperidone was incorporated into sucrose microfibers using centrifugal spinning technology. Fiber morphology was characterized by scanning electron microscopy (SEM). Drug loading (DL), encapsulation efficiency (EE%), and disintegration time were measured. In vitro drug release and cytotoxicity assays were performed using human foreskin fibroblast cells (HFF-1). An in vivo palatability and preference study was conducted in male BALB/c mice to evaluate the acceptability of the formulation compared with a commercial risperidone oral solution. Results: SEM analysis revealed smooth, bead-free, non-porous fibers with uniform morphology and size distribution. The formulation showed a rapid disintegration time of ~3 s, DL of 30 ± 5 µg/mg, and EE% of 60 ± 10%. Approximately 50% of risperidone was released within 15 min. Cytotoxicity testing confirmed that concentrations ≤ 125 µg/mL maintained high cell metabolic activity, indicating biocompatibility. In vivo, the microfiber solution demonstrated a strong preference (93%) compared with the commercial oral solution (30%). Conclusions: Risperidone-loaded sucrose microfibers represent a promising fast-dissolving oral delivery system for children with ASD. This child-friendly formulation improves palatability and compliance while maintaining safety and drug release performance.

Background/Objectives: Skin wounds interrupt the natural anatomy and function of the skin. The body passes through four physiological phases to repair wounds after injury. Since the fibers are more closely related to the extracellular matrix structure, they can be used as scaffolds to accelerate wound closure. Shikonin is a botanical herbal remedy used as an anti-inflammatory agent and for its wound-healing characteristics. Cresols are known for their bactericidal and fungicidal properties, which promote their utilization as a disinfectant in soap. Therefore, this study aimed to formulate shikonin and cresol-loaded nanofibers for a dual wound-healing and antibacterial wound dressing in vitro. Methods: This study demonstrated the effectiveness of the drug-loaded nanofibers against diverse Gram-positive and Gram-negative bacteria using the minimum inhibitory concentration (MIC) and zone of inhibition assays. Results: Scanning electron microscopy images showed successful formulation of shikonin/cresol fibers with an average diameter of 772 ± 152 nm. The encapsulation efficiency and drug loading for the dual drug-loaded fibers were 44 ± 1% and 25 ± 1 µg/mg, respectively, for shikonin, and 38 ± 1% and 21 ± 0.5 µg/mg, respectively, for cresol, with a full release of both drugs achieved after 180 min. The combination of both compounds exhibited a safe concentration of ≤6 µg/mL, with cell viability of >50% in human dermal fibroblasts (HFF-1) after 24 h. The MIC results indicated that the combination was efficient as an antibacterial agent against Gram-positive bacteria at a safe concentration. The shikonin/cresol-loaded fibrous system showed an inhibition zone close to that of the control drugs, suggesting that the drugs have retained their antibacterial activity after electrospinning. Conclusions: This dual drug-loaded fiber system showed a high potential as an antibacterial wound dressing for skin infection injuries. However, in vivo studies are required to assess the safety and efficacy in an animal model of the dual drug-loaded fiber system.